End of Induction (EOI) Curie Scores
For patients undergoing tandem AHCT, the median Curie score at EOI was 0
(range 0 to 23) and the median change in Curie score was -11.5 (range
-27 to 0) from diagnosis to EOI (FIGURE 1B) . The optimal CS cut
point at EOI was 0 for recipients of tandem AHCT. Three-year EFS was
significantly greater in patients with a CS=0 (n=48) vs >0
(n=32) at EOI, 72.9±6.4% vs 46.5±9.1%, p=0.002. Similarly, 3-year OS
was superior in patients with a CS=0 vs >0 at EOI,
83.1±5.5% vs 55.9±9.0%, p=0.015 (TABLE 2) (FIGURE 3A) . When
restricting the analysis to the 56 patients who received tandem
transplant and immunotherapy, EOI CS remained significant, with 3-year
EFS 81.1±6.4% vs 57.9±11.3% for those with a CS=0 (n=37) vs
CS>0 (n=19) respectively; p=0.016. No statistical
difference was noted in OS for this same population, p=0.06.
Outcomes based upon CS at EOI are shown by MYCN status(TABLE 3) (FIGURE 3B-C) . In this small cohort of patients with
either MYCN- amplified or MYCN- NA disease, 3-year EFS was
superior in patients with a CS=0 (vs >0) at EOI.
Relative Curie scores, including either a 50% or 75% reduction in CS
from diagnosis to EOI, were not associated with a statistically
significant difference in EFS or OS in recipients of tandem AHCT(TABLE 2) .